Abstract Library

#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database

Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,

Keywords: Carcinoid syndrome, resources, health economics,

#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Trevisi E, Brizzi M, Espinosa Olarte P, Enguita A,

Keywords: Lung neuroendocrine tumors, tumor side (left versus right), tumor site (peripheric versus central), prognostic factors, survival,

#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)

Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Kaiser K, Webster K, Shaunfield S, Greene G, Yount S,

Keywords: neuroendocrine tumors, priority symptoms, qualitative methods,

#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,

Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,

#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,

Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,